Literature DB >> 29253681

Pre- and long-term postoperative courses of hippocampus-associated memory impairment in epilepsy patients with antibody-associated limbic encephalitis and selective amygdalohippocampectomy.

Niels Hansen1, Leon Ernst2, Theodor Rüber2, Guido Widman2, Albert J Becker3, Christian E Elger2, Christoph Helmstaedter2.   

Abstract

OBJECTIVE: Limbic encephalitis (LE) is defined by mesiotemporal lobe structure abnormalities, seizures, memory, and psychiatric disturbances. This study aimed to identify the long-term clinical and neuropsychological outcome of selective amygdalohippocampectomy (sAH) in drug-resistant patients with temporal lobe epilepsy due to known or later diagnosed subacute LE not responding to immunotherapy associated with neuronal autoantibodies.
METHODS: In seven patients with temporal lobe epilepsy due to antibody positive LE (glutamic acid decarboxylase (GAD65): n=5; voltage-gated potassium channel complex (VGKC), N-methyl d-aspartate receptor (NMDAR): n=1; Ma-2/Ta: n=1) sAH (6 left, 1 right) was performed. Those patients underwent repeated electroencephalography (EEG) recordings, magnetic resonance imaging (MRI) volumetry of the amygdala and hippocampus, and neuropsychological examinations and were followed up for 6-7years on average.
RESULTS: Verbal memory and figural memory were affected in 57% of patients at baseline and 71% at the last follow-up. At the last follow-up, 14% of the patients had declined in verbal memory and figural memory. We observed improved memory in 43% of patients regarding figural memory, but not in a single patient regarding verbal memory. Repeated evaluations across the individual courses reveal cognitive and MRI dynamics that appear to be unrelated to surgery and drug treatment. Three of the seven patients with LE with different antibodies (NMDAR: n=1, Ma-2/Ta: n=1 and GAD65: n=1) achieved persistent seizure freedom along with no accelerated memory decline after surgery. Two of the five GAD65-antibody patients positive with LE showed progressive memory decline and a long-term tendency to contralateral hippocampus atrophy.
CONCLUSIONS: While memory demonstrated some decline in the long run, what is most important is that a progressive decline in memory is seldom found after sAH in patients with LE. Moreover, the dynamics in performance and MRI before and after surgery reveal disease dynamics independent of surgery. Selective amygdalohippocampectomy can lead to seizure freedom, but should be considered as a last resort treatment option for drug-resistant patients with temporal lobe epilepsy due to LE. Particular caution is recommended in patients with GAD65-LE.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Amygdala; Hippocampus; Limbic encephalitis; Memory; Selective amygdalohippocampectomy

Mesh:

Substances:

Year:  2017        PMID: 29253681     DOI: 10.1016/j.yebeh.2017.10.033

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  14 in total

Review 1.  Autoantibody-associated psychiatric syndromes in children: link to adult psychiatry.

Authors:  Niels Hansen; Daniel Luedecke; Berend Malchow; Michael Lipp; Jonathan Vogelgsang; Charles Timäus; Tristan Zindler; Stefan Gingele; Simone Kühn; Jürgen Gallinat; Klaus Wiedemann; Johannes Denk; Nicole Moschny; Jens Fiehler; Thomas Skripuletz; Christian Riedel; Mike P Wattjes; Inga Zerr; Hermann Esselmann; Luise Poustka; Anne Karow; Hans Hartmann; Helge Frieling; Stefan Bleich; Jens Wiltfang; Alexandra Neyazi
Journal:  J Neural Transm (Vienna)       Date:  2021-05-31       Impact factor: 3.575

2.  Comparisons Between Infectious and Autoimmune Encephalitis: Clinical Signs, Biochemistry, Blood Counts, and Imaging Findings.

Authors:  Chen-Na Huang; Xiao-Bing Tian; Shu-Min Jiang; Sheng-Hui Chang; Nan Wang; Ming-Qi Liu; Qiu-Xia Zhang; Ting Li; Lin-Jie Zhang; Li Yang
Journal:  Neuropsychiatr Dis Treat       Date:  2020-11-04       Impact factor: 2.570

Review 3.  Immunotherapy in Autoantibody-Associated Psychiatric Syndromes in Adults.

Authors:  Niels Hansen; Charles Timäus
Journal:  Front Psychiatry       Date:  2021-01-28       Impact factor: 4.157

Review 4.  Diagnostic Value of Structural and Functional Neuroimaging in Autoimmune Epilepsy.

Authors:  Limei Luo; Nian Wei; Jing Wang; Yuemei Luo; Fei Yang; Zucai Xu
Journal:  Contrast Media Mol Imaging       Date:  2020-12-14       Impact factor: 3.161

Review 5.  Current Nosology of Neural Autoantibody-Associated Dementia.

Authors:  Niels Hansen
Journal:  Front Aging Neurosci       Date:  2021-07-28       Impact factor: 5.750

6.  Intravenous methylprednisolone or immunoglobulin for anti-glutamic acid decarboxylase 65 antibody autoimmune encephalitis: which is better?

Authors:  Tao-Ran Li; Yu-Di Zhang; Qun Wang; Xiao-Qiu Shao; Zhi-Mei Li; Rui-Juan Lv
Journal:  BMC Neurosci       Date:  2020-03-30       Impact factor: 3.288

7.  Specific B- and T-cell populations are associated with cognition in patients with epilepsy and antibody positive and negative suspected limbic encephalitis.

Authors:  Christoph Helmstaedter; Niels Hansen; Pitshaporn Leelaarporn; Kerstin Schwing; Demet Oender; Guido Widman; Attila Racz; Rainer Surges; Albert Becker; Juri-Alexander Witt
Journal:  J Neurol       Date:  2020-08-20       Impact factor: 4.849

Review 8.  Prevalence of Neural Autoantibodies in Epilepsy of Unknown Etiology: Systematic Review and Meta-Analysis.

Authors:  Pablo Cabezudo-García; Natalia Mena-Vázquez; Nicolás L Ciano-Petersen; Guillermina García-Martín; Guillermo Estivill-Torrús; Pedro J Serrano-Castro
Journal:  Brain Sci       Date:  2021-03-19

9.  Dysfunctional Learning and Verbal Memory in Patients with Elevated Tau Protein Levels and Serum Recoverin Autoantibodies-Case Series and Review.

Authors:  Niels Hansen; Claudia Bartels; Kristin Rentzsch; Winfried Stöcker; Dirk Fitzner
Journal:  Brain Sci       Date:  2021-12-23

Review 10.  Autoimmune encephalitis with psychiatric features in adults: historical evolution and prospective challenge.

Authors:  Niels Hansen; Charles Timäus
Journal:  J Neural Transm (Vienna)       Date:  2020-10-07       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.